FDA grants quick review for 3 psychedelic drug trials
NBC News
—
The Food and Drug Administration granted a quick review of three experimental psychedelic drugs meant to treat major depression and post-traumatic stress disorder.
NBC News' Erika Edwards reports on the specific drugs under review and how the FDA determines whether they are safe and effective.
- U.S. FDA plans ultra-fast review of three psychedelic drugs following Trump directive CTV News —
- US FDA plans ultra-fast review of 3 psychedelic drugs after Trump directive South China Morning Post —
- FDA grants quick review for 3 psychedelic drug trials NBC News —
- FDA fast-tracks psychedelic drug research following Trump executive order CNBC —
- FDA plans fast review of 3 psychedelic drugs following Trump directive Boston Globe —